Moreover, we first identified the key CXCL13+ T cells and early TLSs in ATC that could make ATC more sensitive to immunotherapy, implying that promoting TLS development could be a promising way to improve the efficacy of immunotherapy for thyroid cancer. This evidence concerns the gene CXCL13 and thyroid gland carcinoma.